Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia.
Emily Mason-OsannAmy E PomeroyAdam C PalmerJerome T MettetalPublished in: Blood cancer discovery (2024)
Preclinical strategies to identify combinations for cancer treatment often focus on identifying synergistic combinations. This study shows that in AML cells combinations that rely on synergy can increase the likelihood of developing resistance, suggesting that combination screening strategies may benefit from a more holistic approach rather than focusing on drug synergy. See related commentary by Bhola and Letai, p. 81. This article is featured in Selected Articles from This Issue, p. 80.